INTRODUCTION
The World Health Organisation suggests that as a leading cause of disability in adults, major depressive disorder (MDD) closely follows cardiovascular disease (1) , but the pathogenesis and underlying aetiology of the disorder remain unclear (2) . Much research has focused on aberrant function in neurotransmitter pathways, especially serotoninergic and noradrenergic systems; however, muscarinic-cholinergic pathways have also been implicated (3) . The receptors in this pathway are G-protein-coupled receptors, central in the control of the acetylcholine response. Specifically, negative feedback on acetylcholine release from cholinergic terminals is mediated by the cholinergic muscarinic 2 receptor (CHRM2) (4, 5) .
The muscarinic -cholinergic system has been implicated in evaluating and learning the salience of sensory stimuli (6) , leading to the suggestion that disruption may modify the perception of emotionally valenced events (7) . A major presynaptic autoreceptor, the M 2 receptor, is highly expressed in the brain (8) , and has been implicated in stress; corticosteroids can enhance M 2 receptor expression (mRNA, protein and function) (9) . Similarly, the administration of a muscarinic agonist to mice produces a significant increase in corticosterone, void of parasympathomimetic side effects (10) , whereas no increase in corticosterone levels is observed in M 2 receptor knockout mice (11) . This indicates that the corticosterone response is mediated by the muscarinic M 2 receptors. Cholinergic hypersensitivity has also been observed in depression, with increased neurophysiological responses in individuals with current or remitted MDD, and exacerbation of depressive symptomotology following administration of muscarinic receptor agonists or acetylcholinesterase inhibitors (3, 6, (12) (13) (14) (4, 16) , and has been studied across phenotypes including Alzheimer's disease (17) , cognition and memory (18 -20) , alcoholism and drug dependence (21, 22) , externalizing disorder (23) and MDD (21, 22, 24) . Three studies have reported evidence of linkage with MDD with markers on chromosome 7 in, or close to, a region containing the CHRM2 gene. An initial report identified linkage with alcohol dependence (25) ; however, these data were later re-analysed with MDD as the phenotype, and the same region showed significant LOD scores (26) . Two further papers report evidence for linkage in the same chromosomal region with both alcohol dependence and MDD (21, 27) , providing further indication that this chromosomal region may be of importance in MDD.
There have been three association studies investigating polymorphisms in the CHRM2 gene in association with mood disorders. Comings et al. (24) investigated one SNP (rs81919921), reporting an association with MDD in women. A more comprehensive investigation of the gene was undertaken by Wang et al. (21) , studying six SNPs in the 5 0 -UTR and 5 in the 3 0 -UTR in the collaborative study on the genetics of alcohol (COGA) sample. Evidence for association with MDD was found with four SNPs in the 5 0 -UTR, and a three marker haplotype comprising of three of these SNPs. A third study (22) also took a comprehensive approach investigating many SNPs across the gene. However, this study was based upon broad phenotype (affective disorders, including bipolar disorder, unipolar disorder and seasonal affective disorders) and did not attempt to replicate the previously reported haplotype, including just two SNPs that Wang et al. (21) studied, neither of which were included in the haplotype the latter group pursued. No evidence for single SNP association was reported, however suggestive and modestly significant haplotypes were described in association with affective disorder.
Using a large clinical unipolar case -control sample from the UK, the aim of the current study was to investigate the four markers previously associated by Wang et al. (21) and the initial three-marker haplotype identified.
RESULTS
The genotypic distributions of the SNPs investigated within the CHRM2 gene are in accordance with Hardy -Weinberg equilibrium (HWE) in the control and the unipolar sample, as a whole and when stratified by gender (P . 0.05). Complete genotypes were available for 97-99% of the individuals across the SNPs. It is possible to calculate an odds ratio of 1.59 [95% confidence interval (CI) 1.18-2.15] for the association observed by Comings et al. (24) on the basis of the frequency data reported in their published paper. The DeCC sample (see Materials and Methods for details) possesses 100% power to detect allelic association with all SNPs if there is a true odds ratio at the previously reported level of 1.59, and even at the more modest level of 1.50. Even if the true odds ratio is 1.30, power to detect allelic association remains above 90% with all the SNPs. However, this drops drastically if the true odds ratio is just 1.18, the lower bound of the 95% CI for the association reported by Comings et al. (24) ( Table 1) .
Single marker analyses of CHRM2
The allelic distribution observed in this sample for the four SNPs is comparable to those reported by Wang et al. (21) . Single-locus analyses yielded no significant genotypic or allelic association with recurrent unipolar depression. None of the 95% CIs of the odds ratios overlapped with the 1.59 odds ratio that we calculated for the association reported by Comings et al. (24) ( Table 2 ).
Haplotype analyses of CHRM2
We tested the same three-marker haplotype as Wang et al. (21) . SNP rs2350786 shows high LD with rs2061174 (r 2 ¼ 0.75, D' ¼ 1.00; Table 3 ) in agreement with previous reports (21) and was excluded. LD between the other SNPs, although comparable, is slightly greater in our sample. The haplotype analysed was rs1824024 -rs2061174 -rs324650, and yielded no significant global x 2 statistic associated with MDD (x 2 ¼ 2.31, P ¼ 0.889). Over 99% of each sample (control and unipolar) was included in the haplotype analyses. The haplotypespecific analyses are shown in Table 4 ; the common haplotypes (T-T-T, G-C-A and T-T-A) make up 85.6% of the observed haplotypes in the unaffected sample. The haplotype with a frequency below 1% (T-C-T) was excluded from analyses, improving statistical power.
DISCUSSION
This study presents no evidence for association with the genetic variants genotyped in the CHRM2 gene in depression. Two of the three previous studies investigating this gene in depression have utilized family samples originally collected for the study of alcohol-and/or drug-abuse or dependence: COGA (21) and MTFS (24) . The third study had only a small 'additional' sample added of individuals diagnosed with MDD (22) , otherwise it too was primarily geared to elucidating the genetic aetiology of alcohol-and drug-dependence. The study of Luo et al. No single-marker or globally significant haplotypic association was observed in the DeCC sample with the three-marker haplotype (rs1824024-rs2061174-rs324650) previously associated in the COGA sample with MDD (21). Wang et al. reported overtransmission of haplotypes G-C-A and G-C-T, and undertransmission of the most common haplotype T-T-T, and a rare haplotype T-C-A. In contrast, haplotype-specific analyses yielded no significant results within the DeCC sample; again this was the case when genders were both combined for analyses, or when they were separated. It is possible that failure to replicate the findings of Wang et al. (21) is because the phenotype of the DeCC sample is not the same as that in the COGA sample. Depression occurring solely in relation to alcohol was an exclusion criterion in the DeCC sample, as was alcohol dependence; however, the COGA study was designed to investigate alcohol dependence and does not differentiate between individuals suffering depression as a consequence of alcohol, or those suffering independent of alcohol. The other single CHRM2 marker study reporting an association with MDD also derived their study-group from an alcohol-and drug-dependence sample (22) . Therefore, it is possible that an association with CHRM2 exists only in depression comorbid with substance misuse.
It is also possible that population structure in previous studies produced false positive results. The DeCC sample was 100% self reported white European origin. In contrast, the COGA sample was 82% Caucasian, 15% African-American and 3% 'other'. The report of Wang et al. (21) on the CHRM2 gene and MDD in the COGA sample did not correct for population stratification, citing the comparatively small size of the African-American sample and the fact that internal controls were used in a family-based analysis. Indeed Luo et al. (22) reported that their observed association with alcohol-and drugdependence with SNPs in the CHRM2 gene was stronger within the African-American sample relative to the Caucasian sample. Unfortunately, they reported no such data on their mooddisorder group, as they were entirely of European-American origin. However, their findings generally support the hypothesis that ethnic differences are important as potential explanations of across-study disparities. It is also worth-noting that the rare three-marker haplotype excluded in the haplotype analysis in the DeCC sample (T-C-T) shows a very different frequency (,1%) from that in the COGA sample (3.8%). No haplotype within the COGA sample falls below the 1% rare haplotype threshold. It is possible that this also is a consequence of ethnic differences. There are known small differences in the allelic distributions of these SNPs between the African-Americans and Caucasians, and larger differences are also observed with the Chinese population (www.ensembl.org) who could have been included with 'other' in the COGA sample. The haplotypic frequency disparity may also be a consequence of differences in LD in the samples. Consistent with this hypothesis is the observation that LD in the DeCC sample is slightly greater than that reported in the COGA sample, which could be the reason less individuals possess the T-C-T haplotype in the DeCC sample. This too could be attributed to population stratification in the US sample. This paper presents the first clinical case -control study investigating CHRM2 in recurrent unipolar depression that is not co-morbid with substance misuse. We have failed to replicate a previous study associating four SNPs in the CHRM2 gene with MDD in the COGA sample (21) , and present no evidence that these markers or a three-marker haplotype (rs1824024 -rs2061174 -rs324650) increase the risk of the disorder. This supports a previous study that failed to find an association with mood disorder and two of the SNPs, rs1824024 and rs3246560 (22); however, the variation covered within the gene through the investigation of these replication markers is 15%. Therefore, it cannot be completely ruled out that the CHRM2 locus is implicated in the genetic aetiology of MDD.
MATERIALS AND METHODS

Study subjects
Individuals (n ¼ 1420; 435 men, 983 women and 2 sex unknown) with recurrent unipolar depression, mean age 47.17 years, were recruited from three clinical UK sites: London, Cardiff and Birmingham. Subjects were identified from psychiatric clinics, hospitals and general medical practices and from volunteers responding to media advertisements. Only subjects, of white European ('Caucasian') parentage, were included if they were over the age of 18 and had experienced 2 or more episodes of unipolar depression of at least moderate severity separated by at least 2 months of remission as defined by the Diagnostic and Statistical Manual 4th edition operational criteria (DSMIV) (28) or the International Classification of Diseases 10th edition operational criteria (ICD10), for unipolar depression (29) . All subjects were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (30, 31) . At the time of interview, interviewers obtained 25 ml of whole blood collected in 37.5 ml (EDTA containing) monovettes. In addition, drops of blood were placed on a Guthrie blood spot card. The blood samples were labelled with a bar code, gently mixed and stored frozen upright in a 2208C freezer pending DNA extraction.
Subjects were excluded if they or a first-degree relative, ever fulfilled criteria for mania, hypomania or schizophrenia.
Subjects were also excluded if they experienced psychotic symptoms that were mood incongruent or present when there was no evidence of a mood disturbance. Other exclusion criteria were intravenous drug use with a lifetime diagnosis of dependency; depression occurring solely in relation to alcohol or substance abuse or depression only secondary to medical illness or medication, and a clear diagnosis of bipolar disorder, schizophrenia, schizo-affective disorder or acute or transient psychotic disorders in first-or second-degree relatives.
The mean age of all the control individuals (n ¼ 1624; 698 men, 922 women and 4 sex unknown) was 42.24 years. They were screened for lifetime ever absence of psychiatric disorder using a modified version of the Past History Schedule (32) . Subjects were excluded if they, or a first-degree relative, ever fulfilled criteria for depression or any other psychiatric disorder. Subjects were also excluded if they scored 10 or above on the Beck Depression Inventory (33), did not return consent, or failed to return cheek swabs. Informed written consent was obtained and buccal mucosa swabs were collected for DNA via the mail. The swab containers were labelled with a bar code pending DNA extraction.
Phenotypic data analysis
All phenotypic information from SCAN interviews and questionnaires was coded by assigning a number to each subject, and removing any personal identifying information. The same codes were used on the blood sample or cheek swab tubes using a bar code system. The phenotypic information was entered into a data file created using Statistical Procedures for the Social Sciences (SPSS) version 12 for Windows for the statistical analyses.
Statistical analysis
To test for deviation from HWE, the Pearson (x 2 ) test statistic and an exact statistic were calculated with the computer program FINETTI (available on http://ihg.gsf.de/cgi-bin/hw/ hwal.pl). Cases and controls were considered separately. This program was also used for calculating allelic odds ratios with 95% CIs. Power was calculated using the PS program (34) . In this program, the method of Schlesselman (35) is used with independent case and control groups for analysis using an uncorrected x 2 test. When the case and control sample sizes are unequal, PS uses the generalization of Casagrande's method proposed by Fleiss (36) . The alternative hypothesis is specified in terms of odds ratios.
Single marker association analysis was carried out using standard contingency table analysis incorporating x 2 tests of independence for each SNP, run in SPSS for Windows (Version 12.0). Two-and three-marker haplotype analyses, and conditional testing, were carried out using UNPHASED (37) and significance assessed utilizing a Monte Carlo method following 10 000 permutations.
DNA genotyping
Genomic DNA was extracted from bloods and cheek swabs collected as described previously (38, 39) . Genotyping data were obtained for 3830 individuals (n ¼ 1408 unipolar cases, 846 bipolar cases and 1576 controls) and was blind to all phenotypic information. A proportion of individuals (n ¼ 1222 cases and 832 controls) were externally genotyped for the four SNPs (rs1824024, rs2061174, rs2350786 and rs324650) using the KASPar system by KBioscience, UK (www.kbioscience.co.uk). The remaining individuals (n ¼ 186 cases and 744 controls) were genotyped at the MRC SGDP Centre using the Taqman w SNP genotyping platform (PE Applied Biosystems, Foster City, CA, USA). The Taqman w assays ordered from Applied Biosystems (Foster City, CA, USA) were: C_11626291_10 (rs2061174), C_1604562_10 (rs2350786), C_3036433_10 (rs1824024) and C_773390_10 (rs324650).
